Sanofi’s venglustat earns Breakthrough Therapy designation in the US for type 3 Gaucher disease. Paris, March 18, 2026. The US Food and Drug Administration (FDA) has granted Bre ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results